BriaCell Therapeutics Corp. announced that its independent Data Safety Monitoring Board issued a fifth consecutive positive recommendation for the company’s pivotal Phase 3 Bria‑ABC study, which evaluates the cell‑based immunotherapy Bria‑IMT in combination with a checkpoint inhibitor in patients with metastatic breast cancer. The DSMB review, held quarterly as required by the study protocol, found no safety concerns and cleared the trial to continue without modifications.
The recommendation confirms that the safety profile of the Bria‑IMT plus checkpoint inhibitor regimen remains acceptable as enrollment progresses toward the planned interim overall‑survival analysis. It also reinforces BriaCell’s strategy to advance the therapy toward regulatory submission, as the study is conducted under FDA Fast Track designation and is being conducted across a 79‑site network. A clean safety record is a critical prerequisite for regulatory approval and can accelerate the drug’s path to market.
Dr. William V. Williams, President and CEO, said, “This marks the fifth consecutive DSMB review supporting the continued conduct of BriaCell’s pivotal Phase 3 Bria‑ABC study. We are encouraged by the DSMB’s ongoing confirmation of the safety profile of the Bria‑IMT regimen and remain focused on advancing this program for patients with limited treatment options. We look forward to providing additional clinical updates as the study progresses.” The company anticipates reporting top‑line data from the Phase 3 study as early as the first half of 2026.
The milestone strengthens BriaCell’s competitive position in the oncology space, bolsters investor confidence, and offers hope to patients with limited treatment options for metastatic breast cancer. A consistent safety record also supports the company’s ability to secure additional funding and maintain its clinical development pipeline.
Bria‑IMT is a cell‑based immunotherapy that stimulates the immune system by producing breast cancer antigens and secreting GM‑CSF to enhance antigen presentation to T‑cells. Phase 2 data showed a median overall survival of 15.6 months in a heavily pre‑treated cohort, with 52% surviving at one year and 32% at two years, and no patients discontinued therapy due to Bria‑IMT‑related side effects. The Phase 3 Bria‑ABC study builds on this safety profile and aims to demonstrate overall survival benefit in a larger, more diverse patient population.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.